CRISPR/Cas9-Based Lateral Flow and Fluorescence Diagnostics

Mark J. Osborn(University of Minnesota), Jakub Tolar(University of Minnesota System)

Bioengineering

February 12, 2021

10.3390/bioengineering8020023

Cited by 45

Related Papers

Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial

|The Lancet|2020|1k

3D Printed Functional and Biological Materials on Moving Freeform Surfaces

|Advanced Materials|2018|242

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Dyskeratosis Congenita

|Biology of Blood and Marrow Transplantation|2013|130

The Minnesota mobile extracorporeal cardiopulmonary resuscitation consortium for treatment of out-of-hospital refractory ventricular fibrillation: Program description, performance, and outcomes

|EClinicalMedicine|2020|116

Allogeneic hematopoietic SCT for alpha-mannosidosis: an analysis of 17 patients

|Bone Marrow Transplantation|2011|92